Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
J-L Lee, J-H Ahn, H Y Lim, S H Park, S H Lee, T M Kim, D-H Lee, Y M Cho, C Song, J H Hong, C-S Kim, H Ahn, J-L Lee, J-H Ahn, H Y Lim, S H Park, S H Lee, T M Kim, D-H Lee, Y M Cho, C Song, J H Hong, C-S Kim, H Ahn
Abstract
Background: Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC).
Patients and methods: Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4 weeks, followed by 2 weeks of rest. The primary end point was overall response rate (RR).
Results: Thirty-one eligible patients were enrolled. Twenty-four patients (77%) had prior nephrectomy. By Memorial Sloan-Kettering Cancer Center criteria, 8 patients (26%) had poor risk and 14 (45%) had intermediate risk. Twenty-two patients had papillary renal cell carcinoma (RCC), and three had chromophobe RCC. Eleven patients had partial response with a RR of 36% (95% confidence interval (CI) 19% to 52%) and an additional 17 patients (55%) had stable disease. Median duration of response was 12.7 months (95% CI 6.3-19.1 months), and median progression-free survival was 6.4 months (95% CI 4.2-8.6 months). At a median follow-up duration of 18.7 months (95% CI 13.7-23.7 months), 13 patients (42%) had died, resulting in an estimated median survival of 25.6 months (95% CI 8.4-42.9 months). Toxicity profiles were commensurate with prior reports.
Conclusions: Sunitinib has promising activity in patients with nccRCC (NCT01219751).
Source: PubMed